Contraception
Volume 64, Issue 4 , Pages 235-241 , October 2001

A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism

  • J. Endrikat

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49-30-468-17864; fax: +49-30-468-18191
    • Schering AG, Müllerstr, 178, D-13342 Berlin, Germany
    • ,
  • C. Klipping

      Affiliations

    • Dinox Medical Investigations, Groenewoudseweg 317, NL-6524TX Nijmegen, Germany
    • ,
  • C. Gerlinger

      Affiliations

    • Schering AG, Müllerstr, 178, D-13342 Berlin, Germany
    • ,
  • A. Ruebig

      Affiliations

    • Schering AG, Müllerstr, 178, D-13342 Berlin, Germany
    • ,
  • W. Schmidt

      Affiliations

    • Universitätskliniken des Saarlandes, Frauenklinik und Poliklinik, D-66421 Homburg/Saar, Germany
    • ,
  • T. Holler

      Affiliations

    • Schering AG, Müllerstr, 178, D-13342 Berlin, Germany
    • ,
  • B. Düsterberg

      Affiliations

    • Schering AG, Müllerstr, 178, D-13342 Berlin, Germany

References 

  1. Düsterberg B, Ellman H, Müller U, et al.  A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol. 1996;10:33–39
  2. Gast J, Grubb G. A review of cycle control with a low-dose oral contraceptive containing 75 μg gestodene, and 20 μg ethinylestradiol. Gynecol Endocrinol. 1998;12(suppl3):31–37
  3. Endrikat J, Düsterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception. 1999;60:269–274
  4. Rosenberg MJ, Lonog SC. Oral contraceptives and cycle control (a critical review of the literature). Adv Contracept. 1992;8(Suppl 1):35–45
  5. Bannemerschult R, Hanker JP, Wünsch C, et al.  A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles. Contraception. 1997;56:285–290
  6. Hite RC, Bannemerschult R, Fox-Kuchenbecker , Turck R, Brill K. Large observational trial of a new low-dose oral contraceptive containing 20 μg levonorgestrel (Mirova®) in Germany. Europ J Contracep Reprod Health Care. 1999;4:7–13
  7. Spona J, Elstein M, Feichtinger W, et al.  Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  8. Späth H. Cluster-analyis-algorithms for classification of objects, and reduction of data (Cluster-Analyse-Algorithmen zur Objektklassifizierung und Datenreduktion). 2nd ed. München, Wien: Oldenbourg, 1977:23.
  9. The Oral Contraceptive, Hemostasis Study Group . An open label, randomized study to evaluate the effects kof seven monophasic oral contraceptive regimens on hemostatic variables. Contraception. 1999;59:345–355
  10. Winkler UH, Schindler AE, Endrikat J, Düsterberg B. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg, and 30 μg ethinylestradiol. Contraception. 1996;53:75–84
  11. Winkler UH, Hölscher T, Schulte H, Zierleyn JP, Collet W, Schindler AE. Ethinylestradiol 20 versus 30 μg combined with 150 μg desogestrel (a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system). Gynecol Endocrinol. 1996;10:265–271
  12. Gaspard IJ, Demeyer F, Jaminet CB, Scheen AJ, Lefrebbvre PJ. Influence of two low-dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use. Gynecol Endocrinol. 1996;10(Suppl 2):179–188
  13. Winkler UH, Daume E, Sudik R, et al.  A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel. Europ J Contracep Reprod Health Care. 1999;4:145–154
  14. Walsh J, Grady D. Treatment of hyperlipidemia in women. J Am Med Assoc. 1995;274:1152–1158
  15. Marsh MS, Crook D, Whitcroft SIJ. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol. 1994;83:19–23
  16. van der Mooren MJ, Lipping C, Van Aken B, Helmerhorst FM, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg, and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels, and carbohydrate metabolism. Europ J Contracep Reprod Health Care. 1999;4(Suppl 2):27–35
  17. Gerstman BB, Piper JM, Tomit DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptives estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;177:32–37
  18. Consensus development meeting: combined oral contraceptives and cardiovascular disease. The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995. Gynecol Endocrinol 1996;10:1–5.

PII: S0010-7824(01)00236-0

Contraception
Volume 64, Issue 4 , Pages 235-241 , October 2001

Article Tools